Astrazeneca shares jump as it kicks off $2bn drug pipeline investment
Astrazeneca’s share jumped in early trading on Friday, as investors cheered plans to bolster its drug pipeline. The pharmaceutical giant’s shares increased 3.1 per cent to £134.50 on Friday morning, as it launched a $2bn (£1.5bn) restructuring programme to boost investment in its drug channel. The FTSE 100 company said the three-year programme would shift [...]
On Friday, investors reacted positively to Astrazeneca's announcement of a $2 billion investment in its drug pipeline, causing the company's shares to rise by 3.1 percent to £134.50 in early trading. This restructuring program, set to span three years, aims to reallocate resources across various business and therapy areas, generating $1.5 billion in annual savings.
Astrazeneca's recent struggles, including failed trials and the loss of patent protection for three major cancer drugs, have contributed to the company's current focus on growth beyond its $80 billion target by 2030.
Despite this investment, the company's share price had previously dropped in the first half of the year due to negative results from trials, such as the heart disease drug Wainua, and concerns over a potential $400 billion merger with Bristol Myers Squibb. However, the Cambridge-based pharmaceutical giant has managed a 7.7 percent share price increase over the past year.
Astrazeneca's third-quarter revenue also rose by seven percent to $16.2 billion, driven by double-digit growth in its oncology, research and development, and rare disease segments. These results surpassed analysts' forecasts and compensated for setbacks from losing patent protection on Farxiga and Brilinta, two major-selling medicines.
The company achieved approval for 47 projects in the first nine months of the year, including four new medicines. Market analyst Adam Vettese from Etoro noted that the market has comprehended Astrazeneca's ability to continue growth even as one of its primary products faces competition from generics, such as Farxiga, now facing challenges in the US market.
Astrazeneca reiterated its full-year revenue growth projections of mid-to-high single-digit percentages, with CEO Pascal Soriot reaffirming that the company is "on track to deliver our 2030 ambition and sustain growth," primarily due to multiple potential blockbuster assets in late-stage development. The company's recent investments in Summit Therapeutics and a partnership with AI therapeutics company Insitro also highlight its commitment to innovation and growth.
Written by urgent.news from City AM's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
